Matilde Navarro - Concepedia

Author

Matilde Navarro

Also Known As

M J Zarauza Navarro, M L Cabanillas Navarro, M Navarro, M. Navarro, M.C. Lorenzo Navarro, Matilde Navarro, Melissa B. Navarro, Mónica Pina Navarro

127

Publications

16.1K

Citations

H-Index

Concepts

All Affiliations

Institut Català d'Oncologia Institut d'Investigació Biomédica de Bellvitge Centro de Investigación Biomédica en Red de Cáncer Universitat de Barcelona Bellvitge University Hospital

About

Matilde Navarro is an author at Institut Català d'Oncologia specializing in medicine, colorectal cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	31	8.6K
2	Public Health	5	5	294
3	Health Sciences	4	4	118
4	Emergency Medicine	1	1	131
5	Environmental Health	1	1	77

Matilde Navarro

Publications

15.5K

Citations

H-Index

Page 1

	Year	Citations
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer Thierry André, C. Boni, Lamia Mounedji-Boudiaf, New England Journal of Medicine	2004	3.6K
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial J-Y Douillard, David Cunningham, AD Roth, The Lancet MedicinePharmacologyColorectal CancerMetastatic Colorectal CancerFirst-line Treatment	2000	3.3K
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial Thierry André, C. Boni, Matilde Navarro, Journal of Clinical Oncology Surgical OncologyCancer ManagementPathologySurgeryOverall Survival	2009	2.3K
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Philippe Rougier, Eric Van Cutsem, Emilio Bajetta, The Lancet Gastrointestinal OncologyMedicineColorectal CancerFluorouracil FailurePharmacotherapy	1998	992
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database Mev Dominguez–Valentin, Julian R. Sampson, Toni T. Seppälä, Genetics in Medicine	2019	615
Cancer risk and survival in <i>path_MMR</i> carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database Pål Møller, Toni T. Seppälä, Inge Bernstein, Gut	2017	544
Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database Pål Møller, Toni T. Seppälä, Inge Bernstein, Gut	2015	531
Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Stefano Landi, Vı́ctor Moreno, Lydie Gioia‐Patricola, PubMed InflammationInflammatory ResponsesAutoimmune DiseaseImmunologyGenetic Epidemiology	2003	318
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer Marc Ychou, Werner Hohenberger, Simon Thézenas, Annals of Oncology Surgical OncologyHepatologyMedicinePharmacologyColorectal Cancer	2009	267
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study Mace L. Rothenberg, John V. Cox, Charles Butts, Annals of Oncology MedicinePharmacologyColorectal CancerPathologyMetastatic Colorectal Cancer	2008	197

Page 1